The biotechnology company specializes in regenerative treatments for ophthalmic diseases by utilizing a novel therapeutic that protects and regenerates corneal nerves. This approach targets the underlying causes of degenerative ophthalmic conditions, enabling patients to experience improved vision and quality of life.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many ophthalmic diseases, such as glaucoma, dry eye disease, and age-related macular degeneration (AMD), involve the degeneration of corneal nerves and retinal ganglion cells, leading to vision loss and reduced quality of life. Current treatments often focus on managing symptoms rather than addressing the underlying nerve damage. There is a need for therapies that can protect and regenerate these damaged nerves to restore visual function.
Solution
Neuroptika is developing novel regenerative treatments for ophthalmic diseases by targeting the underlying causes of nerve degeneration. Their lead compound, NRO-1, is designed to protect and regenerate corneal nerves and retinal ganglion cells. Neuroptika's approach involves delivering therapeutic molecules, such as Calcium/calmodulin-dependent protein kinase II (CaMKII) via intravitreal injection or antibodies that inhibit vitronectin, to promote nerve survival and function. These therapies aim to slow down or stop the progression of diseases like glaucoma, dry AMD, wet AMD, and diabetic retinopathy by preventing further nerve damage and potentially restoring lost visual function.
Target Audience
Neuroptika's primary target audience includes patients suffering from ophthalmic diseases characterized by nerve degeneration, such as glaucoma, dry eye disease, AMD, and diabetic retinopathy, as well as ophthalmologists and retinal specialists seeking disease-modifying treatments.
Features
- NRO-1: A novel therapeutic with the potential to regenerate corneal nerves.
- NRO-CMK: Delivers Calcium/calmodulin-dependent protein kinase II (CaMKII) via single AAV intravitreal injection to protect retinal ganglion cells (RGC).
- NRO-VTN: Inhibits the surface exposed functional domain of vitronectin by delivering an antibody to prevent drusen formation in AMD.
- Targets neurodegenerative glaucoma by protecting retinal ganglion cells, even with normal intraocular pressure.
- Investigating treatments for diabetic retinopathy and diabetic macular edema.
- Completed Phase 1 clinical trial demonstrating safety and tolerability of NRO-1.